相关实验视频

Updated: Jun 10, 2025

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

致病的Th17细胞是TACROLIMUS在ACHR-myasthenia gravis患者中的潜在治疗点

Yingkai Li¹, Pei Chen², Xin Huang²

¹Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Neuromuscular division, Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.

Journal of neuroimmunology

|October 11, 2024

概括

塔克罗利斯 (TAC) 治疗通过减少特定的T辅助细胞17 (Th17) 和IL-17水平,改善了乙胆受体-肌痛性肌痛症 (AChR-MG) 患者的症状. 这突显了TAC在管理MG中的免疫调节作用.

科学领域:

免疫学免疫学免疫学
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

骨髓灰质炎 (MG) 是一种自身免疫性疾病,影响神经肌肉结节.
乙胆受体 (AChR) 抗体是MG的主要原因.
免疫调节疗法对于管理MG至关重要,但机制需要进一步阐明.

研究的目的:

研究TAC对ACHR-MG患者CD4+T细胞子集的影响.
为了将T细胞子集的变化与12周内TAC治疗的临床反应相关联.

主要方法:

一组41名ACHR-MG患者接受了12周的TAC治疗.
根据临床改善,患者被分为响应组 (RG) (n=27) 和非响应组 (n=14).
流细胞计用于分析CD4+T细胞子集 (Th17,致病性Th17,Th1,Th2,Treg,Tfh) 和IL-17水平.

主要成果:

在RG中,TAC治疗显著降低了Th17和致病性Th17细胞.
在RG中,干白素-17 (IL-17) 水平显著下降.
Th1和Tfh细胞略有下降,而Th2和Treg亚组不受TAC的影响.

结论:

塔克罗利斯在ACHR-MG患者中显示出临床益处,可能是通过抑制Th17免疫反应.
这些发现有助于更好地理解TAC在MG管理中的免疫调节机制.
准Th17途径代表了ACHR-MG的一个有前途的治疗策略.

关键词:

卡尔西纽林抑制剂卡尔西纽林抑制剂在这里,我们可以看到MGMGMGMGMG.骨髓灰质炎 (Myasthenia gravis) 是一个严重的疾病.塔克罗利慕斯可以使用.Th17细胞的细胞.

更多相关视频

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.